Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies

被引：0
|
作者：
Park, Yeon Hee
Cortes, Javier
Modi, Shanu
Hurvitz, Sara A.
Bianchini, Giampaolo
Iwata, Hiroji
Shitara, Kohei
Siena, Salvatore
Goto, Yasushi
Ku, Geoffrey Yuyat
Charles, Powell Andrew
Swain, Sandra M.
Arunachalam, Meena
Janek, Martin
Cheng, Yingkai
Chu, Changan
Verma, Purnima
Mathias, Elton
Karnoub, Maha
Rugo, Hope S.
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[2] Quironsalud Grp, IBCC, Pangaea Oncol, Barcelona, Spain
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Univ Washington, Sch Med, Seattle, WA USA
[5] Fred Hutchinson Canc Ctr, Seattle, WA USA
[6] Univ Vita Salute San Raffaele, Milan, Italy
[7] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[8] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[9] Univ Milan, Milan, Italy
[10] Niguarda Canc Ctr, Milan, Italy
[11] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[12] Tisch Canc Inst, Mt Sinai Hosp, New York, NY USA
[13] Georgetown Univ, Washington, DC USA
[14] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[15] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12118
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer
    Tarantino, Paolo
    Lee, Do
    Foldi, Julia
    Soulos, Pamela R.
    Gross, Cary Philip
    Grinda, Thomas
    Winer, Eric P.
    Lin, Nancy U.
    Krop, Ian E.
    Tolaney, Sara M.
    Lustberg, Maryam B.
    Sammons, Sarah L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
    Powell, C. A.
    Modi, S.
    Iwata, H.
    Takahashi, S.
    Nie, K.
    Qin, A.
    Singh, J.
    Taitt, C.
    Verma, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S61 - S62
  • [43] Population Pharmacokinetics of trastuzumab deruxtecan (T-DXd) in HER2positive breast cancer subjects: analyses across 12 Phase 1-3 studies
    Li, Claire
    Henning, Stefanie
    Patel, Kashyap
    Hui, Katrina
    van der Vleuten, Gerly
    Abutarif, Malaz
    Garimella, Tushar
    Khatri, Amit
    CANCER RESEARCH, 2024, 84 (09)
  • [44] Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
    Bartsch, R.
    Berghoff, A. S.
    Furtner, J.
    Marhold, M.
    Bergen, E. S.
    Roider-Schur, S.
    Starzer, A. M.
    Forstner, H.
    Rottenmanner, B.
    Dieckmann, K.
    Bago-Horvath, Z. A.
    Widhalm, G.
    Ilhan-Mutlu, A.
    Minichsdorfer, C.
    Fuereder, T.
    Singer, C. F.
    Weltermann, A.
    Puhr, R.
    Preusser, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S198 - S198
  • [45] Overcoming trastuzumab resistance using trastuzumab deruxtecan (T-DXd), a HER2 targeting antibody drug conjugate, in HER2 amplified gastric cancer.
    Park, Juin
    Jeong, Inhye
    Kang, Sun Kyoung
    Yu, Seo Young
    Kwon, Woo Sun
    Kim, Tae Soo
    Hwang, Jihyun
    Chung, Hyun Cheol
    Rha, Sun Young
    CANCER RESEARCH, 2021, 81 (13)
  • [46] A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
    Fuchs, C.
    Shahidi, J.
    Mathew, L.
    Qin, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S150 - S150
  • [47] Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.
    Janne, Pasi A.
    Goto, Yasushi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kim, Sang-We
    Planchard, David
    Ahn, Myung-Ju
    Smit, Egbert F.
    De langen, Adrianus Johannes
    Perol, Maurice
    Pons-Tostivint, Elvire
    Novello, Silvia
    Hayashi, Hidetoshi
    Shimizu, Junichi
    Kim, Dong-Wan
    Pereira, Kaline
    Cheng, Fu-Chih
    Taguchi, Ayumi
    Cheng, Yingkai
    Goto, Koichi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Im, Seock-Ah
    Iwata, Hiroji
    Curigliano, Giuseppe
    Kim, Sung-Bae
    Chiu, Joanne Wing-Yan
    Pedrini, Jose Luiz
    Li, Wei
    Yonemori, Kan
    Bianchini, Giampaolo
    Loi, Sherene
    Borges, Giuliano Santos
    Wang, Xian
    Bachelot, Thomas
    Nakatani, Shunsuke
    Ashfaque, Shahid
    Liang, Zhengkang
    Egorov, Anton
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
    Oh, D-Y.
    Meric-Bernstam, F.
    Makker, V.
    Oaknin, A.
    Banerjee, S.
    Gonzalez Martin, A.
    Jung, K. H.
    Lugowska, I.
    Manso, L. M.
    Manzano, A.
    Melichar, B.
    Siena, S.
    Stroyakovskiy, D.
    Fielding, A.
    Ma, Y.
    Puvvada, S. D.
    Lee, J-Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1494 - S1495
  • [50] An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01,-02, and-03
    Krop, Ian E.
    Wildiers, Hans
    Hurvitz, Sara A.
    Cortes, Javier
    Im, Seock-Ah
    Iwata, Hiroji
    Andre, Fabrice
    Saura, Cristina
    Modi, Shanu
    Kim, Sung-Bae
    Egorov, Anton
    Mathias, Elton
    Cathcart, Jillian
    Cagnazzo, Antonio
    Cheng, Yingkai
    Park, Yeon Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345